Enhanced therapeutic efficacy of doxorubicin against multidrug-resistant breast cancer with reduced cardiotoxicity

Enhanced therapeutic efficacy of doxorubicin against multidrug-resistant breast cancer with reduced cardiotoxicity

AbstractDoxorubicin (DOX), a commonly used anti-cancer drug, is limited by its cardiotoxicity and multidrug resistance (MDR) of tumor cells. Epigallocatechin gallate (EGCG), a natural antioxidant component, can effectively reduce the cardiotoxicity of DOX. Meanwhile, EGCG can inhibit the expression...

Full description

Bibliographic Details
Main Authors: Tianyu Zhang, Nuannuan Li, Ru Wang, Yiying Sun, Xiaoyan He, Xiaoyan Lu, Liuxiang Chu, Kaoxiang Sun
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Drug Delivery
Subjects:
Cardiotoxicity
multidrug resistance
active targeting
pH-sensitive
immunogenic cell death (ICD)
Online Access:https://www.tandfonline.com/doi/10.1080/10717544.2023.2189118

Internet

https://www.tandfonline.com/doi/10.1080/10717544.2023.2189118

Similar Items